SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014400077> ?p ?o ?g. }

Showing items 1 to 88 of 88 with 100 items per page.

W2014400077 endingPage "216" @default.
W2014400077 startingPage "206" @default.
W2014400077 abstract "Over the past decade, with the advent of molecular technologies, our understanding of the complex mechanisms behind cardiovascular diseases has expanded exponentially. From the identification of inherited single gene disorders to multigenic acquired pathology, the fundamental genetic contributions of these diseases are unquestionable. These developments have led to an enhanced interest in gene-based therapeutic strategies. The ability to alter patterns of gene expression or function in an effort to correct or prevent disease processes forms the basis for “gene therapy.” The delivery of genetic agents and successful manipulation of gene expression in living tissues has been crucial to the potential realization of this exciting technology. The application of this technology not only will affect the overall approach to medical therapies, but likely will improve our ability to treat patients surgically. Complications that limit the long-term efficacy of traditional surgical cardiovascular therapies, such as transplantation and bypass grafting, will greatly benefit from advances in both our understanding and treatment of the genetic and molecular basis of these problems. In this review, we will present the state of gene therapy strategies and the range of methods for genetic intervention that currently exist. We will review the progress and application of this technology toward the improvement of surgical cardiac revascularization, as it applies to molecular neovascularization of the myocardium and the enhancement of bypass graft patency. We will discuss the potential impact gene transfer and genetic engineering principles and technologies may have on cardiovascular surgery and on surgical outcomes. Finally, rapid progress in human genome sequencing and mapping is likely to affect cardiovascular therapeutics and surgery. We believe the integration of the disciplines of gene therapy and genomics and cardiovascular surgery should result in the emergence of a new field of therapy that we term surgiomics. Gene therapy is defined as any manipulation of gene expression or function for the treatment of a specific disease. This manipulation may be achieved either via the introduction of foreign DNA into cells that encode a biologically active transgene or through “transfection” of short chains of nucleic acids known as oligodeoxynucleotides (ODNs) that modify endogenous gene expression in target cells (Fig 1).Gene transfer can result in the expression and replacement of a missing gene product or in the “overexpression” of a native or foreign gene whose product can prevent or reverse a disease process. Many therapeutic settings will demand some degree of control over the duration, location, and level of transgene expression. To this end, researchers have begun to develop gene promoter systems that allow regulation of the spatial or temporal pattern of gene expression. Gene blockade can be accomplished by transfection of cells with either complementary DNAs (cDNAs) encoding antisense or decoy sequences, or with antisense or decoy ODNs. Antisense ODNs are generally 15 to 20 bases in length and are designed to have a sequence that is complementary to a segment of the target gene messenger RNA (mRNA). By binding to the message, it renders the template unavailable for translation into its biologically active product.1Colman A. Antisense strategies in cell and developmental biology.J Cell Sci. 1990; 97: 399-409PubMed Google Scholar Alternately, decoy ODNs are double-stranded chains designed to mimic the chromosomal binding sites of transcription factors (factors that regulate gene expression by binding to chromosomal DNA at specific promoter regions) and act as “decoys,” reducing the availability of transcription factors required for subsequent activation or suppression of target genes.2Bielinska A Schivdasani RA Zhang L Nabel GJ. Regulation of gene expression with double-stranded phosphothioate oligonucleotides.Science. 1990; 250: 997-1000Crossref PubMed Scopus (359) Google Scholar Another form of gene blockade is the use of “ribozymes,” segments of RNA that can act like enzymes to destroy only specific sequences of target mRNA. Ribozymes contain both a catalytic region that can cleave other RNA molecules in a sequence-specific manner and an adjacent sequence that confers the specificity of the target. Although many cells will naturally take up DNA from their extracellular environment in small amounts, such low levels are generally insufficient to achieve a physiologically significant influence on genetic function. Clinical gene therapies will therefore depend on the development of vector systems that enhance the efficiency of in vivo DNA transfer. The “ideal” vector would be capable of safe and highly efficient delivery to all cell types, both proliferating and quiescent, with the opportunity to select either short-term or indefinite gene expression. This ideal vector would also have the flexibility to accommodate genes of all sizes, incorporate control of the temporal pattern and degree of gene expression, and to recognize specific cell types for tailored delivery or expression. Although progress is being made on each of these fronts individually, researchers remain far from possessing a single vector with all of these characteristics. Instead, a spectrum of vectors has evolved, each of which may find a niche in different early clinical gene therapy strategies. Viruses are the most common vehicles for exogenous gene delivery into mammalian cells. Although they take on many distinct forms, all viruses consist of a genetic nucleic acid code encapsulated in a machinery that facilitates gene transfer and, in many cases, gene expression. Recombinant viral particles used as gene transfer vectors are distinguished from their naturally occurring derivative viruses, most importantly by their inability to replicate. This is achieved by deletion or mutation of various genetic elements required for completion of the normal viral life cycle. Instead, therapeutic genes are cloned into the recombinant genome and coupled to the necessary regulatory elements. Just as viral vectors appear to be nature's solution to the problem of efficient gene transfer, the true realization of their technologic potential has been confounded by the biologic barriers that have evolved to protect cells and organisms from viral infection. Not only has the host immunologic response limited the efficacy of viral gene transfer, particularly when repeated administrations are considered, but the inflammatory response to viral antigens has impeded and, at times, negated the therapeutic benefits of transgene expression.3Newman KD Dunn PF Owens JW Schulick AH Virmani R Suckhova G et al.Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia.J Clin Invest. 1995; 96: 2955-2965Crossref PubMed Scopus (263) Google Scholar Engineering of viral genomes does not always preclude residual cytotoxicity in infected cells, and the possibility for regression to replication proficiency or for further mutation and recombination with other virulent viruses in the environment pose biologic hazards that are difficult to quantitate or predict. Retroviruses encode RNA-dependent DNA-polymerases, known as reverse transcriptases, that convert a viral RNA genome to double-stranded DNA.4Danos O Mulligan RC. Safe and efficient generation of recombinant retroviruses and amphotrophic and ecotrophic host ranges.Proc Natl Acad Sci U S A. 1988; 85: 6460-6464Crossref PubMed Scopus (793) Google Scholar The DNA is then inserted into a host chromosome, where stable transgene expression may be possible. For this integration to take place, the infected cell must undergo cell division within a short time after infection, thus limiting the delivery of the DNA to replicating cells. Lentiviruses are another class of retrovirus that can integrate into the host genome in the absence of replication. Although this is an attractive alternative for gene transfer into quiescent cardiovascular cells, safety concerns remain concerning the use of these members of the human immunodeficiency virus family; some concern also exists over mutation into its pathogenic phenotype. Unlike retroviruses, recombinant adenoviruses are capable of infecting nondividing cells and have therefore become the most widely used viral vector for experimental in vivo gene transfer in animal models of cardiovascular disease.5Brody SL Crystal RG. Adenovirus-mediated in vivo gene transfer.Ann N Y Acad Sci. 1994; 716: 90-101Crossref PubMed Scopus (157) Google Scholar The use of adenoviral vectors has been associated with significant immunologic and cytotoxic complications. The immune response and the absence of gene integration significantly limit gene expression, which rarely lasts beyond 2 weeks after adenoviral gene transfer. Researchers are therefore exploring removal of nearly all adenoviral genes, creating “gutless” adenoviruses, both to reduce the immunogenicity of the vector and to increase the size of possible transgene insertions. Adeno-associated virus is a human parvovirus that is not able to replicate unless a helper virus, such as adenovirus or herpes virus, is present in the same cell. Adeno-associated virus has not been linked to human disease and can infect a wide range of target cells, establishing a latent infection by integration into the genome of the cell, thereby yielding stable gene transfer. Unlike retroviruses, adeno-associated viruses can infect nonreplicating cells. However, adeno-associated virus is limited by its small size and hence the size of transgene DNA that can be inserted. In addition, the efficiency of adeno-associated virus vectors for in vivo cardiovascular gene therapy remains to be determined.6Svensson EC Marshall DJ Woodard K Hua L Jiang F Chu L et al.Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors.Circulation. 1999; 99: 201-205Crossref PubMed Scopus (167) Google Scholar Plasmids are circular chains of DNA that were originally discovered as a natural means of gene transfer between bacteria. Naked plasmids can also be used to transfer DNA into mammalian cells. The direct injection of plasmid DNA into tissues in vivo can result in transgene expression, although being limited to a few millimeters surrounding the injection site. Numerous nonviral methods are available to enhance the delivery of plasmid or oligonucleotide DNA into cells in vitro, including calcium phosphate, electroporation, and particle bombardment, but have shown only limited efficiency in vivo. The encapsulation of DNA in artificial lipid membranes (liposomes), primarily cationic liposomes, can facilitate its uptake and cellular transport and provides flexibility in substituting different transgene constructs in comparison with the relatively complex process of constructing recombinant viral vectors. Other substances, such as lipopolyamines and cationic polypeptides, are now being investigated as potential vehicles for enhanced DNA delivery for both gene transfer and gene blockade strategies with ODN. Our collaborators have developed a novel fusigenic-liposome–mediated gene transfer that uses a combination of fusigenic proteins of the Sendai virus (hemagglutinating virus of Japan; HVJ) in conjunction with neutral liposomes.7Dzau VJ Mann MJ Morishita R Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases.Proc Natl Acad Sci U S A. 1996; 93: 11421-11425Crossref PubMed Scopus (166) Google Scholar We8Mann MJ Gibbons GH Hutchinson H Poston RS Hoyt EG Robbins RC et al.Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues.Proc Natl Acad Sci U S A. 1999; 96: 6411-6416Crossref PubMed Scopus (117) Google Scholar have recently reported that the application of a controlled pressurized environment to cardiovascular tissue in a nondistending manner can enhance both ODN and plasmid uptake and nuclear localization. This method has been used for the efficient, ex vivo delivery of DNA to both experimental and human vein grafts and in heart transplantation models. Advances in vector technology, along with the identification of critical pathogenic gene expression, has led to the application of gene therapy technology in animal models of disease in an effort to improve existing cardiovascular surgical therapies. Improved patency of bypass grafts, myocardial neovascularization, and immunomodulation of cardiac grafts are direct examples of investigators' attempts to improve current surgical therapies. Additionally, the application of these technologies may lead to the introduction of cell-based or genetic therapies for the treatment of heart failure as an adjuvant therapy during surgical treatments. The long-term success of surgical revascularization in the lower extremity and coronary circulations has been limited by significant rates of autologous vein graft failure. No pharmacologic approach has been successful at preventing long-term graft diseases such as neointimal hyperplasia or graft atherosclerosis. Gene therapy offers a new avenue for the modification of vein graft biology that might lead to a reduction in clinical morbidity from graft failures. Intraoperative transfection of the vein graft also offers an opportunity to combine intact tissue DNA transfer techniques with the increased safety of ex vivo transfection. A number of studies have documented the feasibility of ex vivo gene transfer into vein grafts using a variety of vector systems. The vast majority of vein graft failures have been linked to the neointimal disease that is part of graft remodeling after surgery. Although neointimal hyperplasia contributes to the reduction of wall stress in vein grafts after bypass, this process can also lead to luminal narrowing of the graft conduit during the first years after operation. Furthermore, the abnormal neointimal layer, with its production of proinflammatory proteins, is believed to form the basis for an accelerated form of atherosclerosis that causes late graft failure. Given the proliferative basis of neointimal hyperplasia, our group chose to target the cell cycle as a means of limiting vein graft disease. Preliminary studies indicated that blockade of at least two cell cycle genes succeeded in preventing significant neointima formation in experimental grafts. We therefore tested a single, intraoperative treatment of vein grafts with a decoy ODN targeting the transcriptional factor E2F, known to be critical in the up-regulation of cell cycle proteins. These genetically engineered vein grafts resisted neointimal hyperplasia for at least 6 months in the rabbit model. Furthermore, these conduits were able to stabilize wall stress in the absence of a neointima via a process of medial hypertrophy and proved resistant to diet-induced graft atherosclerosis. Abnormal endothelial cell function, a significant contributor to graft failure, was also shown to be improved by ODN inhibition of the neointimal disease process. A small-scale prospectively randomized double-blind trial of human vein graft treatment with E2F decoy ODN was conducted in patients undergoing peripheral bypass surgery.9Mann MJ Whittemore AD Donaldson MC Belkin M Conte MS Polak JF et al.Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.Lancet. 1999; 354: 1493-1498Abstract Full Text Full Text PDF PubMed Scopus (383) Google Scholar Efficient delivery of the ODN was accomplished within 15 minutes during the operation by placement of the graft after harvest in a device that exposes the vessel to ODN in physiologic solution and allows simultaneous application of a pressure of 300 mm Hg to all sides of the vessel, avoiding any potential distention injury. This approach resulted in ODN delivery to greater than 80% of graft cells and effectively blocked target cell cycle gene expression, as well as vascular cell proliferation among samples brought back to the laboratory for organ culture analysis. Primary graft failure was defined in this study as graft occlusion, graft revision, or evidence on ultrasonography of a stenosis of greater than 75% at 12 months after surgery in those patients who were not candidates for revision. Although this study was not designed to detect a statistically significant reduction in primary failures, the enrollment of a large proportion of high-risk grafts using poor-quality vein conduits led to an overall event rate that allowed comparison of E2F decoy grafts to untreated controls. Fewer failures were observed in E2F decoy–treated grafts, and, unlike controls, failures were not observed beyond the first 6 months after the operation (Fig 2).Although the efficacy of this approach requires further validation in large-scale multicenter trials, this study demonstrates the safety and feasibility of ex vivo gene therapy of bypass grafts and suggests a possible stabilization of human graft biology similar to that seen in experimental grafts. The success of this study may have broader implications for other forms of native arterial atherosclerosis, such as coronary artery disease, and offers an encouraging glimpse into the future applicability of this therapeutic approach. With the development of virus-mediated gene delivery methods, some investigators have begun to explore the possibility of using these systems ex vivo in autologous vein grafts. Chen and colleagues10Chen SJ Wilson JM Muller DW. Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts.Circulation. 1994; 89: 1922-1928Crossref PubMed Scopus (104) Google Scholar demonstrated the expression of the marker gene β-galactosidase along the luminal surface and in the adventitia of 3-day porcine vein grafts infected with a replication-deficient adenoviral vector at the time of surgery. The vein segments were incubated in a high viral titer suspension for approximately 2 hours before implantation. Others have explored the use of a novel adenovirus-based transduction system, in which adenoviral particles were linked to plasmid DNA via biotin/ streptavidin– transferrin/polylysine complexes. β-Galactosidase expression was documented 3 and 7 days after surgery in rabbit vein grafts that had been incubated for 1 hour with complexes before grafting. Expression was again greatest on the luminal surfaces of the grafts, although the presence of transfected cells in the medial and adventitial layers was also reported. The feasibility of gene transfer in vein grafts has therefore led to the investigation of potential therapeutic end points such as inhibition of neointimal hyperplasia. In a rabbit vein graft model, intraoperative transfection of the senescent cell–derived inhibitor gene, a downstream mediator of the tumor suppressor gene p53, using the HVJ-liposome system, was found to partially inhibit neointima formation. In an alternative approach, George and colleagues,11George SJ Johnson JL Angelini GD Newby AC Baker AH. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein.Hum Gene Ther. 1998; 9: 867-877Crossref PubMed Scopus (184) Google Scholar, 12George SJ Baker AH Angelini GD Newby AC. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins.Gene Ther. 1998; 5: 1552-1560Crossref PubMed Scopus (135) Google Scholar using a replication-deficient adenovirus expressing tissue inhibitor of metalloproteinase-1 or -2, were able to demonstrate decreased neointimal changes in a human saphenous vein organ culture model. In a porcine carotid interposition vein graft model, this same group demonstrated that overexpression of tissue inhibitor of metalloproteinase-3, using a replication-deficient adenovirus, was able to limit neointimal disease, further validating the therapeutic potential of this strategy.13George SJ Lloyd CT Angelini GD Newby AC Baker AH. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3.Circulation. 2000; 101: 296-304Crossref PubMed Scopus (185) Google Scholar Finally, adenovirus overexpression of a nonphosphorylatable, constitutively active Rb gene was also able to demonstrate a reduction in neointima formation.14Schwartz LB Moawad J Svensson EC Tufts RL Meyerson SL Baunoch D et al.Adenoviral-mediated gene transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts.J Vasc Surg. 1999; 29: 874-881Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar Beyond affecting local graft biology, the overexpression of a secreted therapeutic protein by a transduced graft may lead to the treatment of disease in tissues downstream to the location of graft implantation, further expanding the versatility of this bypass conduit. The identification and characterization of “angiogenic” growth factors have created an opportunity to attempt therapeutic “neovascularization” of tissue rendered ischemic by occlusive disease in the native arterial bed. Angiogenesis refers more strictly to the sprouting of new capillary networks from pre-existing vascular structures, whereas vasculogenesis is the de novo development of both simple and complex vessels during embryonic development. Although molecular factors can stimulate angiogenesis in vivo, as clearly established in a number of animal models, it is less certain that these molecules can induce the development of larger, more complex vessels of “neovasculogenesis” in adult tissues that would be capable of carrying significantly increased bulk blood flow. Nevertheless, the possibility of enhancing even microvascular collateralization as a “biologic” approach to the treatment of tissue ischemia has sparked the beginning of human clinical trials in neovascularization therapy. After the first description of the angiogenic effect of fibroblast growth factors (FGFs), an abundance of “pro-angiogenic” factors was discovered to stimulate endothelial cell proliferation, enhanced endothelial cell migration, or both. Vascular endothelial growth factor (VEGF) and two members of the FGF family, acidic FGF (FGF-1) and basic FGF (FGF-2), have received the most attention as potential therapeutic agents for neovascularization. Much debate persists regarding the preferred agent and the optimal route of delivery for angiogenic therapy in the ischemic human myocardium or lower extremity. VEGF may be the most selective agent for stimulating endothelial cell proliferation, although VEGF receptors are also expressed on a number of inflammatory cells including members of the monocyte-macrophage lineage. This selectivity has been viewed as an advantage, because the unwanted stimulation of fibroblasts and vascular smooth muscle cells in native arteries might exacerbate the growth of neointimal or atherosclerotic lesions. Despite this theoretical selectivity, however, the experimental use of VEGF in animal models has been associated not only with capillary growth, but also with the apparent stimulation of vascular smooth muscle cell proliferation and an exacerbation of neointimal hyperplasia after vascular injury. Furthermore, increases in local myocardial VEGF levels, through either direct gene delivery or implantation of genetically engineered myoblasts, has been shown to result in the formation of angiomas rather than organized capillary or vascular networks. The FGFs are believed to be even more potent stimulators of endothelial cell proliferation, but, as their name implies, are much less selective in their pro-proliferative action as well. Optimizing the route of drug delivery depends heavily on the pharmacokinetic properties of the agent. Angiogenesis, however, is a very complex biologic process involving multiple cell types engaged in multiple activities, including extracellular tissue dissolution and remodeling, cell proliferation, cell migration, cell recruitment, and programmed cell death. The role of any single agent must be understood within the complicated orchestration of multiple signaling agents and effectors. Despite the large amount of data that has become available in the past two decades, details of the cellular and molecular mechanisms of angiogenesis remain poorly understood. Still, it is believed that many of the known angiogenic factors, including VEGF and the FGFs, are exquisitely potent and would not, therefore, require large or prolonged dosing regimens. These conclusions are partly based on the results of in vivo experiments in which a broad range of dosing strategies, from implantation of sustained release formulations to single intra-arterial boluses, have been reported to induce similarly successful increases in tissue perfusion.15Ware JA Simons M. Angiogenesis in ischemic heart disease.Nat Med. 1997; 3: 158-164Crossref PubMed Scopus (279) Google Scholar Preclinical studies of angiogenic gene therapy have used a number of models of chronic ischemia. An increase in capillary density was reported in an ischemic rabbit hind limb model after VEGF administration. These results did not differ significantly, regardless of whether VEGF was delivered as a single intra-arterial bolus of protein, plasmid DNA applied to the surface of an upstream arterial wall, or direct injection of the plasmid into the ischemic limb. Direct injection of an adenoviral vector encoding VEGF also succeeded in improving regional myocardial perfusion and ventricular fractional wall thickening at stress in a model of chronic myocardial ischemia induced via placement of a slowly occluding Ameroid constrictor around the circumflex coronary artery in pigs.16Mack CA Patel SR Schwarz EA Zanzonico P Hahn RT Ilercil A et al.Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart.J Thorac Cardiovasc Surg. 1998; 115: 168-176Abstract Full Text Full Text PDF PubMed Scopus (276) Google Scholar A number of studies have demonstrated increased regional blood flow and improved myocardial contractility after perivascular or intravascular delivery of FGF gene transfer agents.15Ware JA Simons M. Angiogenesis in ischemic heart disease.Nat Med. 1997; 3: 158-164Crossref PubMed Scopus (279) Google Scholar A number of phase I safety studies have already been reported in which angiogenic factors or the genes encoding these factors have been administered to a small number of patients.17Ylä-Herttuala S Martin JF Cardiovascular gene therapy.Lancet. 2000; 355: 213-222Abstract Full Text Full Text PDF PubMed Scopus (344) Google Scholar These studies have involved either the use of angiogenic factors in patients with peripheral vascular or coronary artery disease who were not candidates for conventional revascularization therapies, or the application of pro-angiogenic factors as an adjunct to conventional revascularization. The modest doses of either protein factors or genetic material delivered in these studies were not clearly associated with any acute toxicities. Concerns remain, however, regarding the safety of potential systemic exposure to molecules that are known to enhance the growth of possible occult neoplasms or that can enhance diabetic retinopathy and potentially even occlusive arterial disease itself. Despite early enthusiasm, there is also little experience with the administration of live viral vectors in extremely large numbers to a large number of patients, and it is uncertain whether potential biologic hazards of reversion to replication competent states or mutation and recombination will eventually become manifest. The results of two phase II studies investigating the intravascular delivery of either VEGF or FGF-4 have been reported and have failed to demonstrate a statistically significant improvement in exercise tolerance over placebo. These studies may underscore the critical nature of targeting effective delivery of these agents in a human clinical setting. The elucidation of neovascularization as an adaptive and possibly therapeutic phenomenon in the setting of ischemic disease has coincided with the development of what at first seemed to be a simpler approach to revascularization. Transmyocardial laser revascularization (TMR) involves the application of a high-energy laser beam to the epicardial surface of the heart so that tissue vaporization leads to formation of a transmural channel. A percutaneous approach has more recently been developed in which an intraventricular catheter delivers laser energy to the endocardial surface for the creation of channels that pass most but not all of the way through the heart wall. It was originally hoped that these channels would remain patent and provide a source of “direct” revascularization of the myocardium from the ventricular chamber. Although improved myocardial perfusion and function have been demonstrated after TMR in animal models of chronic ischemia, histologic analysis of animal and human specimens has now established that these channels are rapidly occluded via thrombosis and fibrosis. Instead, an increased capillary network has been documented to develop, and it is now widely believed that TMR stimulates an angiogenic response. It is most likely that the effect is part of a generalized “response to injury,” in which inflammatory and healing processes stimulate the growth of new vessels that may ameliorate the underlying ischemic nature of the injured tissue.18Chu V Ku" @default.
W2014400077 created "2016-06-24" @default.
W2014400077 creator A5024656659 @default.
W2014400077 creator A5034010760 @default.
W2014400077 creator A5084429071 @default.
W2014400077 creator A5090663343 @default.
W2014400077 date "2001-02-01" @default.
W2014400077 modified "2023-09-29" @default.
W2014400077 title "Gene therapy and genomic strategies for cardiovascular surgery: The emerging field of surgiomics" @default.
W2014400077 cites W1963497337 @default.
W2014400077 cites W1965164421 @default.
W2014400077 cites W1979477553 @default.
W2014400077 cites W1982224993 @default.
W2014400077 cites W1986928524 @default.
W2014400077 cites W1990187729 @default.
W2014400077 cites W1992346069 @default.
W2014400077 cites W1995226504 @default.
W2014400077 cites W2008193800 @default.
W2014400077 cites W2011404343 @default.
W2014400077 cites W2013720813 @default.
W2014400077 cites W2024628313 @default.
W2014400077 cites W2028456433 @default.
W2014400077 cites W2048303185 @default.
W2014400077 cites W2052612816 @default.
W2014400077 cites W2053704719 @default.
W2014400077 cites W2077425788 @default.
W2014400077 cites W2079930624 @default.
W2014400077 cites W2080225080 @default.
W2014400077 cites W2082301173 @default.
W2014400077 cites W2089752676 @default.
W2014400077 cites W2091987058 @default.
W2014400077 cites W2093457985 @default.
W2014400077 cites W2096034852 @default.
W2014400077 cites W2096737402 @default.
W2014400077 cites W2124946399 @default.
W2014400077 cites W2133117273 @default.
W2014400077 cites W2147231986 @default.
W2014400077 cites W2149733176 @default.
W2014400077 cites W2154736819 @default.
W2014400077 cites W2157572122 @default.
W2014400077 doi "https://doi.org/10.1067/mtc.2001.111211" @default.
W2014400077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11174725" @default.
W2014400077 hasPublicationYear "2001" @default.
W2014400077 type Work @default.
W2014400077 sameAs 2014400077 @default.
W2014400077 citedByCount "13" @default.
W2014400077 crossrefType "journal-article" @default.
W2014400077 hasAuthorship W2014400077A5024656659 @default.
W2014400077 hasAuthorship W2014400077A5034010760 @default.
W2014400077 hasAuthorship W2014400077A5084429071 @default.
W2014400077 hasAuthorship W2014400077A5090663343 @default.
W2014400077 hasBestOaLocation W20144000771 @default.
W2014400077 hasConcept C104317684 @default.
W2014400077 hasConcept C111599444 @default.
W2014400077 hasConcept C177713679 @default.
W2014400077 hasConcept C54355233 @default.
W2014400077 hasConcept C60644358 @default.
W2014400077 hasConcept C71924100 @default.
W2014400077 hasConcept C86803240 @default.
W2014400077 hasConceptScore W2014400077C104317684 @default.
W2014400077 hasConceptScore W2014400077C111599444 @default.
W2014400077 hasConceptScore W2014400077C177713679 @default.
W2014400077 hasConceptScore W2014400077C54355233 @default.
W2014400077 hasConceptScore W2014400077C60644358 @default.
W2014400077 hasConceptScore W2014400077C71924100 @default.
W2014400077 hasConceptScore W2014400077C86803240 @default.
W2014400077 hasIssue "2" @default.
W2014400077 hasLocation W20144000771 @default.
W2014400077 hasLocation W20144000772 @default.
W2014400077 hasOpenAccess W2014400077 @default.
W2014400077 hasPrimaryLocation W20144000771 @default.
W2014400077 hasRelatedWork W1577570641 @default.
W2014400077 hasRelatedWork W1973735945 @default.
W2014400077 hasRelatedWork W1997975349 @default.
W2014400077 hasRelatedWork W2062732066 @default.
W2014400077 hasRelatedWork W2077589865 @default.
W2014400077 hasRelatedWork W2092924259 @default.
W2014400077 hasRelatedWork W2144254115 @default.
W2014400077 hasRelatedWork W2973013189 @default.
W2014400077 hasRelatedWork W4252371801 @default.
W2014400077 hasRelatedWork W4290975843 @default.
W2014400077 hasVolume "121" @default.
W2014400077 isParatext "false" @default.
W2014400077 isRetracted "false" @default.
W2014400077 magId "2014400077" @default.
W2014400077 workType "article" @default.